



Functional Differences between *E. coli* and ESKAPE Pathogen GroES/GroEL

Jared Sivinski,^a Andrew J. Ambrose,^a Iliya Panfilenko,^a Christopher J. Zerio,^a Jason M. Machulis,^a Niloufar Mollasalehi,^{b,c,d} Lynn K. Kaneko,^a Mckayla Stevens,^e Anne-Marie Ray,^e Yangshin Park,^{e,f,g} Chunxiang Wu,^{e,f,g} Quyen Q. Hoang,^{e,f,g} Steven M. Johnson,^e  Eli Chapman^a

^aDepartment of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, Tucson, Arizona, USA

^bDepartment of Chemistry and Biochemistry, University of Arizona, Tucson, Arizona, USA

^cCenter for Innovation in Brain Science, Tucson, Arizona, USA

^dDepartment of Pharmacology, College of Medicine, University of Arizona, Tucson, Arizona, USA

^eDepartment of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, Indiana, USA

^fStark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, Indiana, USA

^gDepartment of Neurology, Indiana University School of Medicine, Indianapolis, Indiana, USA

ABSTRACT As the GroES/GroEL chaperonin system is the only bacterial chaperone that is essential under all conditions, we have been interested in the development of GroES/GroEL inhibitors as potential antibiotics. Using *Escherichia coli* GroES/GroEL as a surrogate, we have discovered several classes of GroES/GroEL inhibitors that show potent antibacterial activity against both Gram-positive and Gram-negative bacteria. However, it remains unknown if *E. coli* GroES/GroEL is functionally identical to other GroES/GroEL chaperonins and hence if our inhibitors will function against other chaperonins. Herein we report our initial efforts to characterize the GroES/GroEL chaperonins from clinically significant ESKAPE pathogens (*Enterococcus faecium*, *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, and *Enterobacter* species). We used complementation experiments in GroES/GroEL-deficient and -null *E. coli* strains to report on exogenous ESKAPE chaperone function. In GroES/GroEL-deficient (but not knocked-out) *E. coli*, we found that only a subset of the ESKAPE GroES/GroEL chaperone systems could complement to produce a viable organism. Surprisingly, GroES/GroEL chaperone systems from two of the ESKAPE pathogens were found to complement in *E. coli*, but only in the strict absence of either *E. coli* GroEL (*P. aeruginosa*) or both *E. coli* GroES and GroEL (*E. faecium*). In addition, GroES/GroEL from *S. aureus* was unable to complement *E. coli* GroES/GroEL under all conditions. The resulting viable strains, in which *E. coli groESL* was replaced with ESKAPE *groESL*, demonstrated similar growth kinetics to wild-type *E. coli*, but displayed an elongated phenotype (potentially indicating compromised GroEL function) at some temperatures. These results suggest functional differences between GroES/GroEL chaperonins despite high conservation of amino acid identity.

IMPORTANCE The GroES/GroEL chaperonin from *E. coli* has long served as the model system for other chaperonins. This assumption seemed valid because of the high conservation between the chaperonins. It was, therefore, shocking to discover ESKAPE pathogen GroES/GroEL formed mixed-complex chaperonins in the presence of *E. coli* GroES/GroEL, leading to loss of organism viability in some cases. Complete replacement of *E. coli groESL* with ESKAPE *groESL* restored organism viability, but produced an elongated phenotype, suggesting differences in chaperonin function, including client specificity and/or refolding cycle rates. These data offer important mechanistic insight into these remarkable machines, and the new strains developed allow for the synthesis of homogeneous chaperonins for biochemical studies and to further our efforts to develop chaperonin-targeted antibiotics.

Citation Sivinski J, Ambrose AJ, Panfilenko I, Zerio CJ, Machulis JM, Mollasalehi N, Kaneko LK, Stevens M, Ray A-M, Park Y, Wu C, Hoang QQ, Johnson SM, Chapman E. 2021. Functional differences between *E. coli* and ESKAPE pathogen GroES/GroEL. *mBio* 12:e02167-20. <https://doi.org/10.1128/mBio.02167-20>.

Editor Robert A. Bonomo, Louis Stokes Veterans Affairs Medical Center

Copyright © 2021 Sivinski et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Address correspondence to Eli Chapman, chapman@pharmacy.arizona.edu.

Received 1 August 2020

Accepted 4 November 2020

Published 12 January 2021

KEYWORDS antibiotic, antimicrobial, chaperone, chaperonin, ESKAPE, GroEL, GroES, HSP10, HSP60

The GroES/GroEL chaperonin system is a nearly megadalton molecular machine that acts as an “Anfinsen cage” in the bacterial cytosol. This cage is formed when GroES interacts with GroEL to form a privileged hydrophilic chamber, where newly synthesized polypeptides or stress-denatured proteins can fold in an isolated chamber sequestered from the crowded cellular environment. The ~800-kDa bis-toroidal tetradecamer GroEL binds unfolded polypeptides and, in an ATP-dependent manner, binds the ~70-kDa heptameric GroES cochaperone, which acts as a lid to cap off the GroEL/GroES folding chamber (1–5). After ~5 to 10 s, ATP is hydrolyzed, which allows for the disassembly of the Anfinsen cage and advances the catalytic cycle. More than 300 different proteins have been shown to interact with GroEL in *Escherichia coli*, ~50 of which have been shown to completely rely on this chaperone system for proper folding (6, 7). Because some of these client proteins are essential, the GroES/GroEL chaperonin is essential for growth under all conditions (8). Based on conserved sequence and structure, it is thought that the homologous GroES/GroEL chaperonins from all organisms should be essential, although this has not been rigorously demonstrated (9, 10). The essential nature of GroES/GroEL and its clients led us to hypothesize that targeting these chaperonin systems might be an effective antibiotic strategy. Supporting this hypothesis, we previously developed a high-throughput screen (11) and identified several inhibitor scaffolds that are effective against bacteria (12–15) and trypanosomes (16); however, we have yet to definitively show that the compounds function by targeting the chaperonins.

Taking advantage of the essential nature of GroES/GroEL in *E. coli*, in the present study, we conducted a series of genetic complementation experiments to study chaperonins from a panel of bacteria known as the ESKAPE pathogens (“ESKAPE” being an acronym for the Gram-positive bacteria *Enterococcus faecium* and *Staphylococcus aureus* and Gram-negative bacteria *Klebsiella pneumoniae*, *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, and *Enterobacter* species) (17). We have been investigating the ESKAPE pathogens due in part to their broad range of evolutionary distances from *E. coli* and in particular because of their clinical relevance to human disease. The GroEL chaperonins from the ESKAPE pathogens are all greater than 50% identical (Fig. 1A) and 70% similar (Fig. 1B; see Table S1 in the supplemental material) to that of *E. coli*. In addition, although GroES chaperonins are not as highly conserved, all of them are greater than 40% identical and 60% similar (Fig. 1C and D; Table S1). Therefore, we hypothesized that GroES/GroEL from the ESKAPE pathogens would efficiently rescue a GroES/GroEL-deficient strain of *E. coli*, called LG6 (18). As in *E. coli*, only a single copy of *groESL* exists within the genomes of the ESKAPE pathogens, and where tested, *groESL* was found to be essential in the ESKAPE organisms (19–23). Surprisingly, we found that not all the ESKAPE chaperonins rescued GroES/GroEL-deficient *E. coli*, with some forming a dominant-negative phenotype. We questioned whether coexpression of endogenous *E. coli* GroES/GroEL (ESL^{Coli}) with the plasmid-containing ESKAPE GroES/GroEL (ESL^{ESKAPE}) could generate mixed-heptameric or tetradecamer chaperones with compromised function. To explore our hypothesis, a stepwise strategy was used starting from GroES/GroEL-deficient *E. coli*, moving next to *groEL*-null *E. coli*, and then finally moving to full replacement of *E. coli groESL* with ESKAPE *groESL*. Ultimately, we show that the function of ESKAPE GroES/GroEL in *E. coli* is dictated by the activity of GroES^{Coli}-GroES^{ESKAPE} hetero-oligomeric complexes, demonstrating functional divergence among the highly conserved chaperonins.

RESULTS

***E. coli* GroES/GroEL shares high amino acid identity and similarity with ESKAPE pathogen GroES/GroEL.** Although structural information has yet to be generated for the ESKAPE GroES/GroEL oligomers, alignment of their primary sequences with *E. coli*




FIG 1 *E. coli* GroES/GroEL shares high amino acid identity and similarity with ESKAPE pathogens GroES/GroEL. Percentages of GroES/GroEL protein identity and similarity were generated from EMBOSS Needle protein alignment of *E. coli* GroES/GroEL and ESKAPE pathogen GroESL. (A) *E. coli* GroEL protein identity compared to ESKAPE GroEL. (B) *E. coli* GroEL protein similarity compared to ESKAPE GroEL. (C) *E. coli* GroES protein identity compared to ESKAPE GroES. (D) *E. coli* GroES protein similarity compared to ESKAPE GroES. EF, *E. faecium*; SA, *S. aureus*; KP, *K. pneumoniae*; AB, *A. baumannii*; PA, *P. aeruginosa*; EC, *E. cloacae*.

MG1655 K-12 GroES/GroEL argues for conserved structure and function (Fig. 1; see Table S1, Table S2, and Fig. S1 in the supplemental material). Amino acid identity is higher between the Gram-negative pathogens and *E. coli* (60.2 to 93.8% for GroES and 75.4 to 96.4% for GroEL) compared to Gram-positive pathogens and *E. coli* (43.3 to 46.4% for GroES and 57.1 to 60.6% for GroEL) (Fig. 1A and C). This trend is also observed for amino acid similarity in the Gram-negative bacteria (78.4 to 97.9% for GroES and 86.7 to 98.0% for GroEL) and Gram-positive bacteria (62.9% for GroES and 75.8 to 77.4% for GroEL) (Fig. 1B and D). Furthermore, predicted ESKAPE GroES and GroEL isoelectric points (4.87 to 5.38 and 4.56 to 5.04, respectively) are congruent with those of *E. coli* GroES and GroEL (5.15 and 4.85, respectively) (Table S2). The isoelectric points of the Gram-positive ESKAPE pathogens are least like those of *E. coli*. Overall, *E. faecium* and *S. aureus* GroES/GroEL contain fewer residues than *E. coli* GroES/GroEL and lack the GGM C-terminal repeat found in *E. coli* GroES/GroEL (24) and other Gram-negative ESKAPE pathogens.

Only *K. pneumoniae*, *A. baumannii*, and *E. cloacae* GroES/GroEL rescue GroES/GroEL-deficient *E. coli*. Plasmids with *pBAD*-driven ESKAPE *groESL* were used to determine if GroES/GroEL from the ESKAPE pathogens could complement a GroES/GroEL-deficient *E. coli* cell line, LG6 (18). LG6 contains a *lac*-promoted *groESL* operon that, in the absence of lactose or IPTG (isopropyl- β -D-thiogalactopyranoside) fails to produce sufficient endogenous GroES/GroEL to sustain viable colonies (25). When LG6 cells were transformed with a plasmid containing *pBAD*-driven *groESL* from the ESKAPE pathogens or *E. coli* (as a positive control) and induced with arabinose, *E. faecium*, *S. aureus*, and *P. aeruginosa* GroES/GroEL chaperone systems could not rescue GroES/GroEL-deficient LG6 cells (Fig. 2A). This was also the case for untransformed LG6 and




FIG 2 Only *K. pneumoniae*, *A. baumannii*, and *E. cloacae* GroES/GroEL rescue GroES/GroEL-deficient *E. coli*. Shown is the LG6 colony number from antibiotic selection plate reported after transformation with individual ESKAPE *pBAD*-promoted *groESL* (Km^r) plasmid, *E. coli pBAD groESL* (Km^r) plasmid, or *pBAD* (Km^r) empty vector. LG6 (Cm^r) did not grow on kanamycin plates. (A) With 0.2% arabinose/kanamycin. (B) With kanamycin only. (C) With 0.5% dextrose–kanamycin. (D) With 500 μ M IPTG–0.2% arabinose–kanamycin. (E) With 500 μ M IPTG–0.5% dextrose–kanamycin. (F) With 500 μ M IPTG–kanamycin. Data represent at least three independent experiments and are reported as mean with standard deviation (SD). EF, *E. faecium*; SA, *S. aureus*; KP, *K. pneumoniae*; AB, *A. baumannii*; PA, *P. aeruginosa*; EC, *E. cloacae*; Coli, *E. coli*; EV, empty vector.

LG6 transformed with *pBAD*-driven empty vector (Fig. 2A). We reasoned this could be due to inappropriate protein levels and thus probed the system with lower levels of ESKAPE and *E. coli* GroES/GroEL. Plasmid antibiotic selection alone (without inducing agent) demonstrated that there was significant transcriptional leakage from the *pBAD* promoter of the *groESL* plasmids, and the same ESKAPE *groESL* plasmids rescued LG6 similarly as when induced with arabinose (compare Fig. 2A and B). Addition of dextrose to the agar plate, to suppress transcriptional leakage, reduced the number of viable colonies of *K. pneumoniae*, *A. baumannii*, and *Enterobacter cloacae*, but failed to produce any viable LG6 colonies in *E. faecium*, *S. aureus*, and *P. aeruginosa* *groESL*-transformed cells (Fig. 2C). Surprised by these results, we induced the chromosomal *E. coli groESL* operon to demonstrate that LG6 could still be rescued by GroES^{Coli}. Despite adequate levels of GroES^{Coli}, we found that in the presence of the ESKAPE *groESL* plasmids, *E. faecium*, *S. aureus*, and *P. aeruginosa* GroES/GroEL-containing cells were unable to produce viable organisms. However, empty vector, *K. pneumoniae*, *A. baumannii*, *E. cloacae*, and *E. coli groESL* plasmid-containing LG6 cells were viable in the presence of wild-type, chromosomal GroES/GroEL stimulated by IPTG induction (Fig. 2D, E, and F).

All *pBAD groESL* plasmids from Gram-negative KAPE pathogens rescued transformed AI90 cells after the *sacB pACYC E. coli groESL* plasmid was counterselected. After ruling out gene dosage (Fig. 2) and codon bias (Table S3) as factors that prevented *E. faecium*, *S. aureus*, and *P. aeruginosa groESL* from rescuing LG6 cells, we sought to determine the cause of these observed dominant-negative phenotypes. To rule out ring mixing between GroEL^{Coli} and GroEL^{ESKAPE} as the cause of the dominant-negative effect, we expressed ESKAPE GroES/GroEL in AI90 *E. coli* cells, in which *groES* is present, but *groEL* is absent from the chromosome. AI90 is maintained by an *E. coli groESL* plasmid capable of negative selection due to the presence of *sacB* within this *pACYC* construct (7). AI90 cells were transformed with ESKAPE *groESL* plasmids in the presence of sucrose (negative *pACYC E. coli groESL sacB* selection) and kanamycin (positive ESKAPE *groESL* selection). This selection shuffled out the *E. coli groESL* plasmid,




FIG 3 All *pBAD groESL* plasmids from Gram-negative ESKAPE pathogens rescue transformed AI90 after the *sacB pACYC E. coli groESL* plasmid is counterselected. (A) Scheme of ESKAPE *groESL* plasmid shuffle into the *E. coli groEL*-null background AI90 strain. (B) AI90 colony number from 5% sucrose–0.2% arabinose–ampicillin selection plate reported after transformation with individual ESKAPE *pBAD groESL* (Amp^r) plasmid, *E. coli pBAD groESL* (Amp^r) plasmid, or *pBAD* (Amp^r) empty vector. The symbol “#” indicates colonies were visualized on these plates but retained mutant *sacB groEL* plasmid. Results represent three independent experiments and are reported as mean with SD. (C) All Gram-negative ESKAPE pathogens rescued *groEL*-deficient AI90 after *sacB pACYC groEL* (Cm^r) plasmid shuffle. Plasmids from surviving colonies after shuffle were isolated and run on 0.5% DNA gel. Ladder, DNA ladder; *sacB*, *sacB pACYC E. coli groESL* plasmid; Coli, *pBAD E. coli groESL*; EC, *pBAD E. cloacae groESL*; AB, *pBAD A. baumannii groESL*; KP, *pBAD K. pneumoniae groESL* plasmid; PA, *pBAD P. aeruginosa groESL* plasmid.

forcing reliance on the ESKAPE *groESL* plasmids for survival. This platform eliminated the possibility of forming mixed-GroEL tetradecamers (active or inactive) and more conclusively tested the compatibility of ESKAPE GroES/GroEL in *E. coli* (Fig. 3A). We found that all ESKAPE pathogen GroELs that could complement LG6 also rescued *E. coli groEL*-null AI90 (Fig. 3B). Because *sacB* is subject to mutations that render its gene product unable to kill cells that retain this plasmid (26), postselection colonies were amplified and plasmid DNA purified to confirm the absence of the *pACYC groESL* plasmids and the presence of an ESKAPE *groESL* plasmid (Fig. 3C). *P. aeruginosa* GroES/GroEL was able to complement AI90, but not LG6, supporting our previous observation that *P. aeruginosa* GroEL formed inactive/underactive mixed-GroEL rings in the presence of *E. coli* GroEL (Fig. 2) and is responsible for the dominant-negative effect seen in LG6. This observation could not explain the lack of AI90 *E. coli* rescue in the presence of *E. faecium* or *S. aureus* GroEL, although *E. faecium* GroEL may be incompatible with *E. coli* GroES in this system.

Viable ESKAPE *groESL* knock-ins were generated by λ -red recombineering in MG1655. Because AI90 contains *groES* on the chromosome, we sought to eliminate the possibility of generating inactive GroES^{Coli}-GroES^{ESKAPE} mixed complexes within the *E. coli* chaperonin complex. To accomplish this, *E. coli groESL* was replaced by ESKAPE *groESL* using λ -red recombination (27, 28) (Fig. 4A). Because of the high base pair identity between the Gram-negative ESKAPE pathogen and *E. coli groESL*, complete knock-ins for these organisms could not initially be generated. Lower base pair homology between *E. faecium* and *E. coli* was sufficient for complete knock-in of *E. faecium groESL* into the *E. coli groESL* operon. The *E. faecium groESL* strain was then used as a template to knock in *groESL* from the remaining ESKAPE pathogens, and each




FIG 4 Viable ESKAPE *groESL* knock-ins were generated by λ -red recombineering in MG1655. (A) Due to high sequence identity between ESKAPE pathogens and *E. coli groESL*, only MG Δ *groESL::EF groESL* (Cam^r) could be obtained from knock-in (lower *groESL* sequence homology compared to Gram-negative pathogens). From this knock-in, *K. pneumoniae*, *A. baumannii*, *P. aeruginosa*, and *E. cloacae groESL* knock-ins were generated. Full *S. aureus groESL* knock-in could not be obtained. (B) PCR products for MG1655 and knock-ins for all ESKAPE pathogens using primers flanking the *groESL* gene visualized on agarose gel. Coli, *E. coli* MG1655 WT *groESL*; EF, MG Δ *groESL::EF groESL* (Cam^r); SA, MG Δ *groESL::SA groESL* (Cam^r) partial knock-in; KP, MG Δ *groESL::KP groESL* (Cam^r); AB, MG Δ *groESL::AB groESL* (Cam^r); PA, MG Δ *groESL::PA groESL* (Cam^r); EC, MG Δ *groESL::EC groESL* (Cam^r).

successful knock-in cell line was confirmed by sequencing. In the absence of background *E. coli* GroES or GroEL, we discovered that all but one of the ESKAPE pathogen GroES/GroEL chaperone systems could replace *E. coli groESL* in MG1655 (Fig. 4B). The ability of *E. faecium* to rescue in this context, but not in AI90, indicates that GroES ring mixing between *E. faecium* and *E. coli* may produce a dominate-negative phenotype. It should not be discounted that GroES^{Coli} and GroEL^{*E. faecium*} may not interact or may form a trapped complex incapable of refolding clients. Complete *S. aureus groESL* knock-in was not possible using this system, but we have observed that *S. aureus* GroES/GroEL forms inclusion bodies when expressed in BL21 cells with host GroES/GroEL. The underlying biochemical reason for this remains unknown and is under investigation.

Coexpression of GroEL^{ESKAPE} and *E. coli* GroEL^{D473C/532Δ} forms nonfunctional-tetradameric GroEL hetero-oligomers. The genetic data from the AI90 rescue and λ -red recombineering experiments argued for the formation of mixed GroEL complexes, but we wanted to demonstrate mixed complex formation and to determine if these had compromised biochemical function. It has been previously shown that coexpression of GroEL^{Coli} and GroEL^{Coli-mutant} monomers form mixed GroEL tetradecamers with monomer integration directly correlated with the level of expression of each GroEL monomer type (29, 30). To investigate the formation of GroEL hetero-oligomers in *E. coli*, pBAD-driven GroEL^{ESKAPE} (expressed alone in its respective knock-in strain Fig. 4) (Fig. 5A), *laclq-Ptac* GroEL^{D473C/532Δ} (expressed alone in BL21 *E. coli*) (Fig. 5B), or both were briefly coexpressed in BL21 (Fig. 5C). Overexpressed GroEL was first purified by ion exchange and then incubated with thiopropyl Sepharose (TPS) resin and




FIG 5 Coexpression of GroEL^{ESKAPE} and *E. coli* GroEL^{D473C/532Δ} forms nonfunctional-tetradecameric GroEL hetero-oligomers. (A) GroEL^{ESKAPE} was expressed in its respective knock-in strain (Fig. 4), purified by Q Sepharose FF (FFQ), and incubated with thiopropyl Sepharose (TPS) resin, but does not bind to resin. (B) GroEL^{D473C/532Δ} (cysteine and truncation mutant) was expressed in BL21, purified by FFQ, captured on TPS resin, and then eluted with increasing concentrations of DTT. (C) GroEL^{ESKAPE} was coexpressed with GroEL^{D473C/532Δ} in BL21, purified by FFQ, captured on TPS resin, and then eluted with increasing concentrations of DTT. (D) GroEL^{D473C/532Δ} runs at a lower molecular weight than GroEL^{ESKAPE} by SDS-PAGE. Captured hetero-oligomer DTT elution fractions, made up of GroEL^{ESKAPE} and GroEL^{D473C/532Δ} displays two bands, representing a mixed-GroEL ring. (E) Denatured (DTT, heat, and SDS treated) or nondenatured samples were run on a 4 to 10% native gradient gel and visualized by Coomassie brilliant blue staining. The fractions analyzed were non-DTT fraction GroEL^{*P. aeruginosa*} (PA), DTT fraction GroEL^{D473C/532Δ} (532Δ), and DTT fraction GroEL^{*P. aeruginosa*/D473C/532Δ} mixed complex (PA/Δ). (F) Denatured (DTT, heat, and SDS treated) or native samples were run on a 4 to 10% native gradient gel and visualized by Coomassie brilliant blue staining. The fractions analyzed were non-DTT fraction GroEL^{*E. faecium*} (EF), DTT fraction GroEL^{D473C/532Δ} (532Δ), and DTT fraction GroEL^{*E. faecium*/D473C/532Δ} mixed complex (EF/Δ). (G) Malachite green ATPase assay using 50nM GroEL and 100 μM ATP measured at 660 nm over time. Black, GroEL^{D473C/532Δ}; red, GroEL^{*P. aeruginosa*}; blue, GroEL^{*E. faecium*}; pink, GroEL^{*P. aeruginosa*/D473C/532Δ}; green, GroEL^{*E. faecium*/D473C/532Δ}; gold, ATP only (spontaneous ATP hydrolysis).

allowed to air oxidize. It is expected that the GroEL cysteine mutant (D473C/532Δ) will form a covalent bond with the TPS resin and elute after reduction with dithiothreitol (DTT), whereas GroEL^{ESKAPE} will be found in the flowthrough and not in the DTT-eluted fractions because it lacks the reactive cysteine. Furthermore, to differentiate between GroEL^{ESKAPE} and GroEL^{D473C/532Δ}, active truncated *E. coli* GroEL (532Δ mutant) was used to determine GroEL identity by SDS-PAGE (Fig. 5D). Coexpressed GroEL^{D473C/532Δ} and GroEL^{*P. aeruginosa*} protein eluted with DTT from TPS resin was found to be a tetradecamer




FIG 6 ESKAPE GroEL domain replacement by *E. coli* GroEL domains produces functional chimeras capable of rescuing GroES/GroEL-deficient *E. coli*. Chimeras were tested for their ability to rescue LG6 in cases where ESKAPE GroEL formed a dominant-negative phenotype. All plasmids contain *E. coli groES* upstream of the *groEL* chimera. (A) *E. coli* GroEL tetradecamers and monomer (PDB 1SX3) with labeled apical (gray), intermediate (teal), and equatorial (forest green) domains. (B) Outline of GroEL domains from N to C terminus. Equatorial (EQ; forest green), intermediate (I; teal), and apical (A; gray) domains. (C) Replacing the *P. aeruginosa* (PA) equatorial domain with the *E. coli* (Coli) equatorial domain and replacing the *E. faecium* (EF) equatorial and apical domains with *E. coli* equatorial and apical domains produced viable (green checkmark) LG6 colonies when these chimeras were expressed from *pBAD*-promoted plasmids. All other chimeras could not rescue LG6 (red X mark).

by native PAGE (Fig. 5E). The DTT-eluted fraction species was present as a double band by PAGE under denaturing conditions, indicating the formation of hetero-oligomeric GroEL *in vivo*. (Fig. 5E). This experimental design was replicated using GroEL^{D473C/532Δ} and GroEL^{*E. faecium*} which yielded similar results (Fig. 5F). Importantly, these GroEL hetero-oligomers showed severely impaired ATPase activity (Fig. 5G) compared to purified homo-oligomers generated using strains from Fig. 4 or GroEL^{D473C/532Δ} expressed in BL21 alone.

ESKAPE GroEL domain replacement by *E. coli* GroEL domains produces functional chimeras capable of rescuing GroES/GroEL-deficient *E. coli*. Based upon the *E. faecium* and *P. aeruginosa* GroES/GroEL dominant-negative phenotype in LG6 (Fig. 2) and the formation of GroEL^{ESKAPE} and GroEL^{D473C/532Δ} hetero-oligomers (Fig. 5), we investigated domain (Fig. 6A and B) incompatibilities that could be responsible for the lack of GroEL hetero-oligomer activity *in vivo*. GroEL chimeras consisting of *E. coli*/*P. aeruginosa* or *E. coli*/*E. faecium* domain swaps were generated and tested for their ability to rescue LG6 (Fig. 6). Chimeric *groEL* was QuickStep cloned (31) into *pBAD*-promoted plasmids with upstream *E. coli groES* present. Expression of *P. aeruginosa* GroEL with the equatorial domain replaced by *E. coli* rescued LG6, but not *E. coli* GroEL with the equatorial domain replaced by *P. aeruginosa* (Fig. 6C). *E. faecium* GroEL with *E. coli* equatorial and apical domains, but not *E. coli* equatorial domain replacement alone, was required for functional rescue of LG6 (Fig. 6C). These results suggest *P. aeruginosa* and *E. faecium* GroEL equatorial domains, in a mixed oligomer with *E. coli* GroEL, may disrupt positive and/or negative ring allostery and loss of chaperonin function. Furthermore, incompatibility of the *E. faecium* apical domain in the presence of *E. coli* GroES may contribute to the dominant-negative phenotype seen in Fig. 2.




FIG 7 ESKAPE *groESL* knock-ins present with an elongated phenotype. *MGΔgroESL::ESKAPEgroESL* (*Cm*¹) cells show an elongated phenotype at various temperatures compared to the parent strain, *MG1655*, between 24 and 42°C. The 400× images were captured for each strain after growth to mid-log phase in LB medium without antibiotic at stated temperatures. *Coli*, *E. coli* *MG1655* at 24°C (left) and 42°C (right); *EF*, *MGΔgroESL::EF groESL* at 24°C (left) and 42°C (right); *KP*, *MGΔgroESL::KP groESL* at 24°C (left) and 42°C (right); *AB*, *MGΔgroESL::AB groESL* at 24°C (left) and 42°C (right); *PA*, *MGΔgroESL::PA groESL* at 24°C (left) and 42°C (right); *EC*, *MGΔgroESL::EC groESL* at 24°C (left) and 42°C (right). The scale bar represents 80.5 μm.

ESKAPE *groESL* knock-ins display similar growth kinetics and GroES/GroEL induction at various temperatures compared to the parent strain, but present with elongated phenotypes. The *MG1655* wild-type strain and ESKAPE *groESL* knock-in strains were grown to mid-log phase at 24, 30, 37, or 42°C (for clarity, we only show data for 24 and 42°C) and imaged by bright-field microscopy at a total magnification of 400×. *MG1655* and *A. baumannii groESL* knock-in strains did not display phenotypic abnormalities (Fig. 7). However, *E. faecium*, *K. pneumoniae*, and *E. cloacae groESL* knock-in strains displayed elongated phenotypes at 24°C, but not 42°C (Fig. 7), which is indicative of compromised GroEL function since GroEL is required for FtsZ function (7). *P. aeruginosa groESL* knock-ins displayed a normal phenotype at 24°C, but mild elongation compared to other strains at 42°C (Fig. 7). Despite these morphological changes at various temperatures, the growth rates of the ESKAPE *groESL* knock-in strains compared to the wild-type strain over 24 h appear unaffected from 24 to 42°C (Fig. 8A to D). To test the *groESL* operon response to heat stress, wild-type and ESKAPE knock-in strain GroES/GroEL induction at 24°C was compared to that in cells grown at 24°C and shifted to 42°C for 5 min. All strains were found to have heat-inducible GroES/GroEL as measured by SDS-PAGE, indicating preservation of functional *groE* operons (Fig. 8E). GroES/GroEL levels at 24 or 42°C were not found to be correlated with growth rate or phenotypic changes noted in Fig. 7

DISCUSSION

Previous studies that replaced *E. coli* GroES/GroEL with homologs such as Cpn10/Cpn60 from *Rhizobium leguminosarum* or human mitochondrial Hsp10/Hsp60 have generated viable *E. coli* (32, 33). This type of complementation lends to the idea that chaperonin amino acid conservation between species parallels with similar client scopes. Therefore, it is not surprising that the intrinsic refolding actions among these systems are sufficient to sustain other organisms in some cases. Although complete replacement of *E. coli* GroES/GroEL with the chaperonins from other organisms is possible (33, 34), experiments where exogenous chaperonins were used to rescue GroES/GroEL-deficient *E. coli*, LG6 (18), have produced unexpected results (35–38). The most intriguing example came from the Mande group, where they studied the ability of *Mycobacterium tuberculosis* GroEL2 and *E. coli*/*M. tuberculosis* GroEL chimeras to rescue GroES/GroEL-deficient *E. coli* (39). Although *M. tuberculosis* GroEL2 is essential for *M. tuberculosis* survival, this chaperonin could not rescue GroES/GroEL-deficient *E. coli*




FIG 8 ESKAPE *groESL* knock-ins display similar growth kinetics and GroES/GroEL induction at various temperatures compared to the parent strain. MG1655Δ*groESL*::ESKAPE *groESL* (Cm^r) shows similar growth kinetics and GroEL/ES induction compared to the parent strain, MG1655, between 24 and 42°C. In three independent experiments and reported as mean with SD, growth in LB medium without antibiotic at the stated temperature was measured by OD₆₀₀ over time to determine growth rate of each individual strain. (A) Growth at 24°C. (B) Growth at 30°C. (C) Growth at 37°C. (D) Growth at 42°C. Black, MG1655; red, MGΔ*groESL*::EF *groESL* (Cm^r); blue, MGΔ*groESL*::AB *groESL* (Cm^r); green, MGΔ*groESL*::KP *groESL* (Cm^r); pink, MGΔ*groESL*::PA *groESL* (Cm^r); open/white, MGΔ*groESL*::EC *groESL* (Cm^r). (E) Whole-cell lysates from *E. coli* and ESKAPE pathogens from MG1655 or knock-in strains expressing the respective GroES/GroEL were analyzed via SDS-PAGE. The black arrows indicate the positions of GroEL (upper) and GroES (lower). The lane numbers 24 and 42 represent 24 and 42°C for 5 min, respectively. Coli, *E. coli*; EF, MGΔ*groESL*::EF *groESL*; KP, MGΔ*groESL*::KP *groESL*; AB, MGΔ*groESL*::AB *groESL*; PA, MGΔ*groESL*::PA *groESL*; EC, MGΔ*groESL*::EC *groESL*.

despite significant amino acid identity with that of *E. coli* GroEL. Several chimeras that were generated in these studies existed as tetradecamers and could prevent aggregation of citrate synthase, but they could not rescue GroES/GroEL-deficient *E. coli*. This suggests that the GroEL chimeras were assembled as nonfunctional tetradecamers capable of trapping denatured protein, but not able to refold clients *in vivo*. We




FIG 9 Dominant-negative phenotypes were observed either from hetero-oligomeric *E. coli*/ESKAPE GroEL or hetero-oligomeric GroES and GroEL, but complete replacement of *E. coli groESL* with ESKAPE *groESL* restored the organism's viability and resulted in an elongated phenotype. The overall model is presented, including GroES/GroEL (PDB 1PCQ) showing *E. coli* GroES/GroEL (teal/forest green), ESKAPE GroES/GroEL (brick red/gray), and hetero-oligomeric GroES/GroEL (teal and brick red, forest green and gray) and viable (blue) or nonviable (red) *E. coli* cells with a normal or elongated phenotype.

hypothesized that expression of GroEL^{Coli} and GroEL^{ESKAPE} in *E. coli* could lead to the generation of GroEL tetradecamers containing a mixture of GroEL^{Coli} and GroEL^{ESKAPE} subunits (Fig. 9). Because the refolding cycle of GroEL is dependent on the highly coordinated movement of multiple domains synchronized between subunits, positive allostery within the ring and/or negative allostery between the rings (40) could be altered by incorporation of dissimilar GroEL subunits. Some of these mixed tetradecamers may be hypofunctional or nonfunctional, perhaps capable of trapping misfolded protein, but unable to refold misfolded proteins *in vivo*. Organisms with multiple HSP60 isoforms seem to have evolved a mechanism to prevent mixture of endogenous HSP60s. Several groups have probed this and found that mixed endogenous oligomers were present at undetectable or very low levels (9, 41, 42); however, exceptions do exist (43, 44). Despite this, coexpression of GroEL^{Coli} and GroEL^{Coli-mutant} subunits can produce mixed GroEL tetradecamers and have been used to study *E. coli* GroEL function (29, 30).

E. coli strains were generated in which *E. coli groESL* was replaced by ESKAPE pathogen *groESL* to compare the extent to which these conserved chaperonin systems could function in *E. coli*. We predicted that the modest differences in amino acid similarity, isoelectric point, and total residue number between ESKAPE and *E. coli* GroES/GroEL (Table S2) were unlikely to cause divergence in chaperonin function or client recognition. Therefore, it was reasonable to predict that this set of chaperonin systems could complement a GroES/GroEL-deficient *E. coli* cell line. We discovered that the expression of GroES/GroEL from *E. faecium*, *S. aureus*, and *P. aeruginosa* in GroES/GroEL-deficient *E. coli* LG6 produced a dominant-negative phenotype that was not the result of codon bias or inappropriate gene dosage (Fig. 2; Table S3). Conversely, three other Gram-negative pathogens were able to rescue this GroES/GroEL-deficient cell line, including *A. baumannii*, whose GroEL sequence is least like *E. coli* GroEL compared to the other Gram-negative pathogen GroEL. ESKAPE pathogen GroES/GroEL that were unable to rescue LG6 undermined cellular viability in ways other than lack of expression; this was evident when GroES^{Coli} was expressed from the chromosome of LG6 in the presence

of ESKAPE pathogen *groESL* plasmid (Fig. 2F). Expression of GroES/GroEL from the LG6 chromosome produced cellular rescue in the presence of *E. coli*, *K. pneumoniae*, *A. baumannii*, and *E. cloacae* *groESL* plasmids or empty vector. However, when *E. faecium*, *S. aureus*, or *P. aeruginosa* *groESL* plasmids were present, these still failed to rescue despite the expression of GroES/GroEL from the chromosome of LG6. Together, these observations indicate that GroESL^{Coli} and GroESL^{ESKAPE} were being translated within LG6. However, in the presence of *E. faecium*, *S. aureus*, or *P. aeruginosa* chaperonin systems, viable LG6 colonies were not observed.

We next set out to test if the formation of mixed-nonfunctional GroEL complexes was responsible for the observed dominant-negative effect in *E. coli* by removing GroEL^{Coli} from the background of *E. coli* strain AI90, which retains a chromosomal copy of *groES*, but not *groEL* (Fig. 3). Here, AI90 is maintained by a plasmid copy of *groESL*, which can be selected against in the presence of sucrose. The formation of mixed-GroEL complexes is not possible in this system due to negative selection of the *E. coli* *groESL* and positive selection for ESKAPE *groESL* plasmid. GroEL ring mixing at the level of translation would be eliminated due to the absence of the *E. coli* *groEL*. This hypothesis was strengthened by the fact that *P. aeruginosa*, which previously could not rescue *E. coli*, was now able to rescue. We attribute this change to the loss of GroEL ring mixing, which was likely responsible for the dominant-negative phenotype seen with the *P. aeruginosa* GroES/GroEL chaperone system when expressed in the presence of GroEL^{Coli} in LG6. This observation does not explain the lack of rescue for Gram-positive chaperonin systems from *E. faecium* and *S. aureus*. It is possible that the presence of *E. coli* GroES and *E. faecium* or *S. aureus* GroES may disrupt the efficient refolding of clients due to a perturbed GroES-GroEL interaction and/or GroES function.

Next, we completely removed the possibility of GroESL^{Coli} and GroESL^{ESKAPE} subunit mixing for both GroES and GroEL by replacing *E. coli* *groESL* with ESKAPE *groESL*, while maintaining the upstream and downstream components of the *E. coli* *groE* operon (Fig. 4). Along with the Gram-negative ESKAPE pathogen chaperonin systems, which were found to rescue in earlier experiments, Gram-positive *E. faecium* *groESL* knock-in was now able to rescue in the absence of GroESL^{Coli}.

Previous work in *E. coli* has shown that coexpression of GroEL^{Coli} and GroEL^{Coli-mutant} produced mixed tetradecamers (29, 30). This observation, along with work from the Lund and Mandé groups, inspired the hypothesis that the coexpression of GroESL^{Coli} and GroESL^{ESKAPE} could produce the same phenomenon. This mixture of subunits could operate with enough functionality to maintain viable *E. coli* within some chaperone systems, but not others. Formation of mixed-GroEL complexes between *E. coli* chaperonin and *E. faecium*, *S. aureus*, and *P. aeruginosa* chaperonins, respectively, may perturb positive allostery within the GroEL ring and/or negative allostery between GroEL rings such that efficient refolding of essential gene products is compromised. This scenario would ultimately lead to loss of cell viability (8). Coexpression of GroEL^{ESKAPE} and GroEL^{D473C/532Δ} demonstrated that tetradameric GroEL hetero-oligomers were formed *in vivo* (Fig. 5). Furthermore, *P. aeruginosa*-*E. coli* and *E. faecium*-*E. coli* hetero-oligomers were found to be essentially devoid of ATPase activity (Fig. 5G), supporting our hypothesis regarding the dominant-negative phenotypes seen in the LG6 rescue experiment (Fig. 2).

Incompatibilities between GroEL^{ESKAPE} and GroEL^{Coli} domains were determined by generating GroEL chimeras (with the plasmid containing *E. coli* *groES* upstream of chimeric *groEL*) and screening for the functional rescue of LG6. For *P. aeruginosa* GroEL, rescue was possible by replacing the equatorial domain with the *E. coli* equatorial domain. For GroEL^{*E. faecium*} to rescue LG6, it was required that both the equatorial and apical domains be replaced by the *E. coli* equatorial and apical domains (Fig. 6C). Cochaperonin specificity has been documented (45); therefore, it is possible that chaperoning ability is compromised if *E. coli* GroES cannot efficiently interact with the *E. faecium* apical domain. It is recognized that the lack of a traditional GGM repeat in the C-terminal tail of GroEL may contribute to premature client release and decreased rate of

refolding (46–48); however, replacement of the GroEL^{*E. faecium*} equatorial domain with that of GroEL^{*E. coli*} (which contains the C-terminal GGM repeat) did not aid in the rescue of A190 chimeric GroEL^{*E. faecium*}. Furthermore, a traditional C-terminal GGM repeat was not required for GroESL^{*E. faecium*} rescue of *E. coli* (Fig. 4).

Each of the *groESL* knock-in strains displayed phenotypic changes at various temperatures, except for *A. baumannii* (Fig. 7). However, basal levels of GroES/GroEL or heat stress induction of knock-in ESKAPE *groESL* did not appear to affect growth rate compared to wild-type (Fig. 8). Inefficient FtsZ refolding by the GroES/GroEL chaperonin system (7, 49) may be responsible for the phenotypic changes seen with some of the ESKAPE *groESL* knock-in strains. It remains to be determined if these GroESL^{ESKAPE} chaperonins have divergent client scopes that are specific to their respective hosts, and this opens the possibility that their structure, allostery, and/or refolding cycle rates may differ to accommodate their own proteome.

Conclusion. We herein report a stepwise approach to study the ability of GroESL^{ESKAPE} chaperonin systems to rescue chaperonin-deficient *E. coli*. We found that the coexpression of GroESL^{*E. coli*} and GroESL^{ESKAPE} generates mixed-subunit oligomers, some of which are non-functional and affect organism survival. These results build upon previous attempts to study exogenous GroES/GroEL within *E. coli* where background GroESL^{*E. coli*} was present. This work highlights the need to eliminate background GroES/GroEL from the host strain as a requisite for recombinant expression to further study exogenous chaperonin systems. Future efforts will involve characterization of ESKAPE GroES/GroEL using the ESKAPE *groESL* knock-in strains we have generated. We wish to determine if, despite high conservation between ESKAPE and *E. coli* GroES/GroEL, these chaperone systems have evolved to refold different scopes of clients. Furthermore, these strains can be used to express ESKAPE GroES/GroEL without interference from host strain GroES/GroEL. Additionally, elucidation of ESKAPE GroEL allostery, GroES-GroEL interactions, and GroES/GroEL structures will be pursued.

MATERIALS AND METHODS

Plasmids and strains. *pBAD*-promoted ESKAPE and *E. coli groESL* plasmids were generated by polymerase incomplete primer extension (PIPE) cloning using pSpeedET as the vector component and genomic DNA from *Enterococcus faecium* ATCC 51559, *Staphylococcus aureus* ATCC 25923, *Klebsiella pneumoniae* ATCC 700603, *Acinetobacter baumannii* ATCC 19606, *Pseudomonas aeruginosa* ATCC 47085, *Enterobacter cloacae* ATCC 13047, and MG1655 K-12 *groESL* as insert components. *pBAD*-promoted chimera plasmids included *E. coli groES* upstream of chimeric *groEL* and were generated by QuickStep cloning (31). *lacIq-Ptac GroEL*^{D473C/532Δ} mutagenesis was performed using the Naismith method (50). Plasmid transformation into LG6 (from Horwich lab) was done by incubation of cells with 100 ng of plasmid for 20 min on ice, followed by 45 s of heat shock at 42°C. Cells were immediately returned to wet ice and diluted with 1 ml SOB (super optimal broth) medium after 2 min of incubation. Transformants were shaken for 1 h at 37°C, with or without induction/suppression agents (arabinose/dextrose), and plated at multiple dilutions on separate agar-antibiotic ± 0.2% arabinose or 0.5% dextrose. This same procedure was used for A190, with exception of addition of 5 to 10% sucrose to agar plates.

Gene knock-in. ESKAPE *groESL* was knocked-in to the MG1655 K-12 *groE* operon using modified Datsenko-Wanner protocol (27, 28). MG1655 K-12 cells transformed with λ -red pKD46 plasmid were grown to an optical density at 600 nm (OD₆₀₀) of 0.2 prior to induction with 0.2% arabinose. Cells were made electrocompetent after growth to an OD₆₀₀ of 0.35 to 0.4 using several washes with ice-cold water and 10% glycerol. ESKAPE *groESL* genes were individually cloned into pKIKOarsB using traditional methods. Insertion cassette PCR products (including 50-bp overhangs covering upstream and downstream of the MG1655 K-12 *groE* operon) were transformed into MG1655 K-12 λ -red cells by electroporation using Bio-Rad Gene Pulser Xcell with 0.2-cm Gene Pulser electroporation cuvettes ($C = 25 \mu\text{F}$; $PC = 200 \Omega$; $V = 2.5 \text{ kV}$). Cells were shaken at 37°C in SOB medium for 3 h and plated on agar-antibiotic. Colonies that arose were picked and grown in LB medium/antibiotic, lysed by boiling at 100°C for 10 min, and then used as the DNA template in a PCR mixture containing primers that flank the *groE* operon. PCR products of potential knock-in colonies were sent for sequence confirmation. The chromosomal antibiotic resistance marker was removed using FLP-recombinase.

Microscopy. Knock-in strains or MG1655 K-12 cells were grown to an OD₆₀₀ of 0.6 in LB medium and prepared in triplicate to be imaged after growth at 24 or 42°C. Live cells were diluted and added to Fisherbrand microscope slides prior to imaging on a Nikon Eclipse 50i microscope at a total magnification of 400 \times . Image colors were modified in Microsoft PowerPoint.

Bacterial growth rate. Knock-in strains or MG1655 K-12 cells were grown overnight in LB medium and prepared in triplicate after being diluted to an OD₆₀₀ of 0.050. Diluted samples were grown at 24, 30, 37, or 42°C, with OD₆₀₀ measurements taken at various time points, after which a growth curve was generated using GraphPad Prism.

Chromosomal GroESL expression. ESKAPE knock-in strains or MG1655 K-12 cells were grown to an OD_{600} of 0.6 at 24°C and then subjected to 5 min of heat shock at 42°C or continued growth at 24°C. Cells were pelleted, and supernatant was obtained by lysis with radioimmunoprecipitation assay (RIPA) buffer containing Halt protease cocktail (Thermo) and 1 mM phenylmethylsulfonyl fluoride (PMSF; Sigma), followed by centrifugation at $22,500 \times g$ for 30 min at 4°C. Supernatant was diluted with Laemmli buffer and heated to 100°C for 10 min, then loaded onto a 15% polyacrylamide denaturing gel and resolved by electrophoresis. GroES and GroEL protein bands were visualized after staining with Coomassie blue.

ATPase activity. The malachite green assay (51) was used to detect the presence of inorganic phosphate post-ATP hydrolysis by GroEL. GroEL (50 nM) and ATP (100 μ M) were incubated at room temperature in reaction buffer (50 mM Tris [pH 7.4], 50 mM KCl, 10 mM $MgCl_2$, 1 mM DTT), with 50- μ l aliquots removed from reaction mixture and added to 100 μ l of malachite green in a 96-well clear plate (Greiner 655101) read at various time points using a SpectraMax ID5 plate reader at 660 nm.

GroEL purification. *pBAD GroEL^{ESKAPE}* and *lacIq-Ptac GroEL^{D473C/532Δ}* were transformed into BL21 in a stepwise fashion and induced for 45 min at 37°C using 0.2% arabinose and 0.5 mM IPTG in LB medium. Mixed complexes were first purified by Q Sepharose FF chromatography and then loaded onto thiopropyl Sepharose 4B resin and eluted with increasing amounts of DTT. Expression of GroEL^{ESKAPE} was done by transformation of *pBAD GroEL^{ESKAPE}* into the respective knock-in strain (Fig. 4) and induced with 0.2% arabinose for 4 h at 37°C after the culture reached an OD_{600} of 0.6. GroEL^{D473C/532Δ} expression was done by transformation of *lacIq-Ptac GroEL^{D473C/532Δ}* into BL21 and induced with 0.5 mM IPTG for 4 h at 37°C after the culture reached an OD_{600} of 0.6. Purification was carried out by Q Sepharose FF and TPS chromatography.

Native PAGE. *E. coli* GroEL^{D473C/532Δ}, GroEL^{ESKAPE}, or *E. coli* GroEL^{D473C/532Δ} and GroEL^{ESKAPE} heterooligomers were run under nonreducing conditions in 1 \times native sample buffer (3 \times 3 ml glycerol, 6.4 ml H₂O, bromophenol blue, 0.6 ml 50 \times running buffer) over 10 h at 80 V in 1 \times native running buffer (50 \times 7.5 g tris-base, 36 g glycine, H₂O to 250 ml) on a 4 to 10% native gel (37.5:1 acrylamide/bis, APS [ammonium persulfate], TEMED [*N,N,N',N'*-tetramethylethylenediamine], Tris [pH 6.8 stacking, pH 8.8 resolving], H₂O). Separate samples were also run on the same gel after 5 min of heat denaturation in native sample buffer including 2% SDS and 10% β -mercaptoethanol (BME). Gels were stained in Coomassie blue and visualized by white light transillumination.

Data availability. Supporting information associated with this article can be found in the online version, which includes *E. coli* and ESKAPE pathogen amino acid conservation as well as codon usage for ESKAPE *groESL*.

SUPPLEMENTAL MATERIAL

Supplemental material is available online only.

FIG S1, PDF file, 0.4 MB.

TABLE S1, PDF file, 0.1 MB.

TABLE S2, PDF file, 0.05 MB.

TABLE S3, PDF file, 0.3 MB.

ACKNOWLEDGMENTS

Research reported in this publication was supported by the National Institute of General Medical Sciences (NIGMS) of the National Institutes of Health (NIH) under Award no. R01GM120350. Q.Q.H., C.W., and Y.P. additionally acknowledge support by NIH grants 5R01GM111639 and 5R01GM115844. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. This work was also supported in part by startup funds from the IU School of Medicine (S.M.J.) and the University of Arizona (E.C.).

We declare no competing financial interests.

Conceptualization, Q.Q.H., S.M.J., and E.C.; Methodology, J.S., A.K.A., I.P., Y.K.K., Y.P., and C.W.; Validation, J.S., A.J.A., I.P., Y.P., C.W., C.J.Z., J.M.M., N.M., L.K.K., M.S., and A.-M.R.; Investigation, J.S., A.J.A., I.P., Y.P., C.W., C.J.Z., J.M.M., N.M., L.K.K., M.S., and A.-M.R.; Writing—Original Draft, J.S.; Writing—Review & Editing, J.S., A.J.A., I.P., Y.P., C.W., C.J.Z., J.M.M., N.M., L.K.K., M.S., A.-M.R., Q.Q.H., S.M.J., and E.C.; Funding Acquisition, Q.Q.H., S.M.J., and E.C.; Resources, Q.Q.H., S.M.J., and E.C.; Supervision, Q.Q.H., S.M.J., and E.C.

REFERENCES

- Ambrose A, Fenton W, Mason DJ, Chapman E, Horwich AL. 2015. Unfolded DapA forms aggregates when diluted into free solution, confounding comparison with folding by the GroEL/GroES chaperonin system. *FEBS Lett* 589:497–499. <https://doi.org/10.1016/j.febslet.2015.01.008>.
- Ellis RJ. 1994. Molecular chaperones. Opening and closing the Anfinsen cage. *Curr Biol* 4:633–635. [https://doi.org/10.1016/s0960-9822\(00\)00140-8](https://doi.org/10.1016/s0960-9822(00)00140-8).
- Hendrix RW. 1979. Purification and properties of groE, a host protein involved in bacteriophage assembly. *J Mol Biol* 129:375–392. [https://doi.org/10.1016/0022-2836\(79\)90502-3](https://doi.org/10.1016/0022-2836(79)90502-3).
- Horwich AL, Fenton WA, Chapman E, Farr GW. 2007. Two families of chaperonin: physiology and mechanism. *Annu Rev Cell Dev Biol* 23:115–145. <https://doi.org/10.1146/annurev.cellbio.23.090506.123555>.
- Saibil HR, Zheng D, Roseman AM, Hunter AS, Watson GMF, Chen S, Auf der Mauer A, O'Hara BP, Wood SP, Mann NH, Barnett LK, Ellis RJ. 1993. ATP

- induces large quaternary rearrangements in a cage-like chaperonin structure. *Curr Biol* 3:265–273. [https://doi.org/10.1016/0960-9822\(93\)90176-O](https://doi.org/10.1016/0960-9822(93)90176-O).
6. Kerner MJ, Naylor DJ, Ishihama Y, Maier T, Chang H-C, Stines AP, Georgopoulos C, Frishman D, Hayer-Hartl M, Mann M, Hartl FU. 2005. Proteome-wide analysis of chaperonin-dependent protein folding in *Escherichia coli*. *Cell* 122:209–220. <https://doi.org/10.1016/j.cell.2005.05.028>.
 7. Chapman E, Farr GW, Usaite R, Furtak K, Fenton WA, Chaudhuri TK, Hondorp ER, Matthews RG, Wolf SG, Yates JR, Pypaert M, Horwich AL. 2006. Global aggregation of newly translated proteins in an *Escherichia coli* strain deficient of the chaperonin GroEL. *Proc Natl Acad Sci U S A* 103:15800–15805. <https://doi.org/10.1073/pnas.0607534103>.
 8. Fayet O, Ziegelhoffer T, Georgopoulos C. 1989. The groES and groEL heat shock gene products of *Escherichia coli* are essential for bacterial growth at all temperatures. *J Bacteriol* 171:1379–1385. <https://doi.org/10.1128/jb.171.3.1379-1385.1989>.
 9. Lund PA. 2009. Multiple chaperonins in bacteria—why so many? *FEMS Microbiol Rev* 33:785–800. <https://doi.org/10.1111/j.1574-6976.2009.00178.x>.
 10. Lund PA. 2001. Microbial molecular chaperones. *Adv Microb Physiol* 44:93–140. [https://doi.org/10.1016/S0065-2911\(01\)44012-4](https://doi.org/10.1016/S0065-2911(01)44012-4).
 11. Johnson SM, Sharif O, Mak PA, Wang H-T, Engels IH, Brinker A, Schultz PG, Horwich AL, Chapman E. 2014. A biochemical screen for GroEL/GroES inhibitors. *Bioorg Med Chem Lett* 24:786–789. <https://doi.org/10.1016/j.bmcl.2013.12.100>.
 12. Abdeen S, Kunkle T, Salim N, Ray A-M, Mammadova N, Summers C, Stevens M, Ambrose AJ, Park Y, Schultz PG, Horwich AL, Hoang QQ, Chapman E, Johnson SM. 2018. Sulfonamido-2-arylbenzoxazole GroEL/ES inhibitors as potent antibacterials against methicillin-resistant *Staphylococcus aureus* (MRSA). *J Med Chem* 61:7345–7357. <https://doi.org/10.1021/acs.jmedchem.8b00989>.
 13. Abdeen S, Salim N, Mammadova N, Summers CM, Frankson R, Ambrose AJ, Anderson GG, Schultz PG, Horwich AL, Chapman E, Johnson SM. 2016. GroEL/ES inhibitors as potential antibacterials. *Bioorg Med Chem Lett* 26:3127–3134. <https://doi.org/10.1016/j.bmcl.2016.04.089>.
 14. Kunkle T, Abdeen S, Salim N, Ray A-M, Stevens M, Ambrose AJ, Victorino J, Park Y, Hoang QQ, Chapman E, Johnson SM. 2018. Hydroxybiphenylamide GroEL/ES inhibitors are potent antibacterials against planktonic and biofilm forms of *Staphylococcus aureus*. *J Med Chem* 61:10651–10664. <https://doi.org/10.1021/acs.jmedchem.8b01293>.
 15. Washburn A, Abdeen S, Ovechikina Y, Ray A-M, Stevens M, Chitre S, Sivinski J, Park Y, Johnson J, Hoang QQ, Chapman E, Parish T, Johnson SM. 2019. Dual-targeting GroEL/ES chaperonin and protein tyrosine phosphatase B (PtpB) inhibitors: a polypharmacology strategy for treating *Mycobacterium tuberculosis* infections. *Bioorg Med Chem Lett* 29:1665–1672. <https://doi.org/10.1016/j.bmcl.2019.04.034>.
 16. Abdeen S, Salim N, Mammadova N, Summers CM, Goldsmith-Pestana K, McMahon-Pratt D, Schultz PG, Horwich AL, Chapman E, Johnson SM. 2016. Targeting the HSP60/10 chaperonin systems of *Trypanosoma brucei* as a strategy for treating African sleeping sickness. *Bioorg Med Chem Lett* 26:5247–5253. <https://doi.org/10.1016/j.bmcl.2016.09.051>.
 17. Mulani MS, Kamble EE, Kumkar SN, Tawre MS, Pardesi KR. 2019. Emerging strategies to combat ESKAPE pathogens in the era of antimicrobial resistance: a review. *Front Microbiol* 10:539. <https://doi.org/10.3389/fmicb.2019.00539>.
 18. Horwich AL, and, Willison KR. 1993. Protein folding in the cell: functions of two families of molecular chaperone, hsp 60 and TF55-TCP1. *Philos Trans R Soc Lond B Biol Sci* 339:313–326. <https://doi.org/10.1098/rstb.1993.0030>.
 19. Ramage B, Erolin R, Held K, Gasper J, Weiss E, Brittnacher M, Gallagher L, Manoel C. 2017. Comprehensive arrayed transposon mutant library of *Klebsiella pneumoniae* outbreak strain KPN1H1. *J Bacteriol* 199:e00352-17. <https://doi.org/10.1128/JB.00352-17>.
 20. Persyn E, Sassi M, Aubry M, Broly M, Delanou S, Asehounne K, Caroff N, Crémet L. 2019. Rapid genetic and phenotypic changes in *Pseudomonas aeruginosa* clinical strains during ventilator-associated pneumonia. *Sci Rep* 9:4720. <https://doi.org/10.1038/s41598-019-41201-5>.
 21. Lewin GR, Stacy A, Michie KL, Lamont RJ, Whiteley M. 2019. Large-scale identification of pathogen essential genes during coinfection with sympatric and allopatric microbes. *Proc Natl Acad Sci U S A* 116:19685–19694. <https://doi.org/10.1073/pnas.1907619116>.
 22. Gallagher LA, Ramage E, Weiss EJ, Radey M, Hayden HS, Held KG, Huse HK, Zurawski DV, Brittnacher MJ, Manoil C. 2015. Resources for genetic and genomic analysis of emerging pathogen *Acinetobacter baumannii*. *J Bacteriol* 197:2027–2035. <https://doi.org/10.1128/JB.00131-15>.
 23. Chaudhuri RR, Allen AG, Owen PJ, Shalom G, Stone K, Harrison M, Burgis TA, Lockyer M, Garcia-Lara J, Foster SJ, Pleasance SJ, Peters SE, Maskell DJ, Charles IG. 2009. Comprehensive identification of essential *Staphylococcus aureus* genes using transposon-mediated differential hybridisation (TMDH). *BMC Genomics* 10:291. <https://doi.org/10.1186/1471-2164-10-291>.
 24. Kumar CM, Mande SC, Mahajan G. 2015. Multiple chaperonins in bacteria—novel functions and non-canonical behaviors. *Cell Stress Chaperones* 20:555–574. <https://doi.org/10.1007/s12192-015-0598-8>.
 25. Fenton WA, Kashi Y, Furtak K, Horwich AL. 1994. Residues in chaperonin GroEL required for polypeptide binding and release. *Nature* 371:614–619. <https://doi.org/10.1038/371614a0>.
 26. Muylers JP, Zhang Y, Benes V, Testa G, Ansoerg W, Stewart AF. 2000. Point mutation of bacterial artificial chromosomes by ET recombination. *EMBO Rep* 1:239–243. <https://doi.org/10.1093/embo-reports/kvd049>.
 27. Serra-Moreno R, Acosta S, Hernalsteens JP, Jofre J, Muniesa M. 2006. Use of the lambda Red recombinase system to produce recombinant prophages carrying antibiotic resistance genes. *BMC Mol Biol* 7:31. <https://doi.org/10.1186/1471-2199-7-31>.
 28. Datsenko KA, Wanner BL. 2000. One-step inactivation of chromosomal genes in *Escherichia coli* K-12 using PCR products. *Proc Natl Acad Sci U S A* 97:6640–6645. <https://doi.org/10.1073/pnas.120163297>.
 29. Motojima F, Chaudhry C, Fenton WA, Farr GW, Horwich AL. 2004. Substrate polypeptide presents a load on the apical domains of the chaperonin GroEL. *Proc Natl Acad Sci U S A* 101:15005–15012. <https://doi.org/10.1073/pnas.0406132101>.
 30. Chapman E, Farr GW, Fenton WA, Johnson SM, Horwich AL. 2008. Requirement for binding multiple ATPs to convert a GroEL ring to the folding-active state. *Proc Natl Acad Sci U S A* 105:19205–19210. <https://doi.org/10.1073/pnas.0810657105>.
 31. Jajesniak P, and, Wong TS. 2015. QuickStep-cloning: a sequence-independent, ligation-free method for rapid construction of recombinant plasmids. *J Biol Eng* 9:15. <https://doi.org/10.1186/s13036-015-0010-3>.
 32. Nielsen KL, McLennan N, Masters M, Cowan NJ. 1999. A single-ring mitochondrial chaperonin (Hsp60-Hsp10) can substitute for GroEL-GroES in vivo. *J Bacteriol* 181:5871–5875. <https://doi.org/10.1128/JB.181.18.5871-5875.1999>.
 33. Ivic A, Olden D, Wallington EJ, Lund PA. 1997. Deletion of *Escherichia coli* groEL is complemented by a *Rhizobium leguminosarum* groEL homologue at 37°C but not at 43°C. *Gene* 194:1–8. [https://doi.org/10.1016/S0378-1119\(97\)00087-5](https://doi.org/10.1016/S0378-1119(97)00087-5).
 34. Shah R, Large AT, Ursinus A, Lin B, Gowrinathan P, Martin J, Lund PA. 2016. Replacement of GroEL in *Escherichia coli* by the group II chaperonin from the Archaeon *Methanococcus maripaludis*. *J Bacteriol* 198:2692–2700. <https://doi.org/10.1128/JB.00317-16>.
 35. Kumar CMS, Khare G, Srikanth CV, Tyagi AK, Sardesai AA, Mande SC. 2009. Facilitated oligomerization of mycobacterial GroEL: evidence for phosphorylation-mediated oligomerization. *J Bacteriol* 191:6525–6538. <https://doi.org/10.1128/JB.00652-09>.
 36. Qamra R, Mande SC. 2004. Crystal structure of the 65-kilodalton heat shock protein, chaperonin 60.2, of *Mycobacterium tuberculosis*. *J Bacteriol* 186:8105–8113. <https://doi.org/10.1128/JB.186.23.8105-8113.2004>.
 37. Qamra R, Srinivas V, Mande SC. 2004. *Mycobacterium tuberculosis* GroEL homologues unusually exist as lower oligomers and retain the ability to suppress aggregation of substrate proteins. *J Mol Biol* 342:605–617. <https://doi.org/10.1016/j.jmb.2004.07.066>.
 38. Sielaff B, Lee KS, Tsai FT. 2011. Structural and functional conservation of *Mycobacterium tuberculosis* GroEL paralogs suggests that GroEL1 is a chaperonin. *J Mol Biol* 405:831–839. <https://doi.org/10.1016/j.jmb.2010.11.021>.
 39. Chilukoti N, Kumar CM, and, Mande SC. 2016. GroEL2 of *Mycobacterium tuberculosis* reveals the importance of structural pliability in chaperonin function. *J Bacteriol* 198:486–497. <https://doi.org/10.1128/JB.00844-15>.
 40. Yifrach O, and, Horovitz A. 1995. Nested cooperativity in the ATPase activity of the oligomeric chaperonin GroEL. *Biochemistry* 34:5303–5308. <https://doi.org/10.1021/bi00016a001>.
 41. Lund PA, van der Vies SM. 2000. Determination of chaperonin activity in vivo. *Methods Mol Biol* 140:75–96.
 42. Gould PS, Burgar HR, Lund PA. 2007. Homologous cpn60 genes in *Rhizobium leguminosarum* are not functionally equivalent. *Cell Stress Chaperones* 12:123–131. <https://doi.org/10.1379/csc-227r.1>.
 43. Zhao Q, Liu C. 2017. Chloroplast chaperonin: an intricate protein folding machine for photosynthesis. *Front Mol Biosci* 4:98. <https://doi.org/10.3389/fmolb.2017.00098>.
 44. Zeilstra-Ryalls J, Fayet O, Georgopoulos C. 1991. The universally

- conserved GroE (Hsp60) chaperonins. *Annu Rev Microbiol* 45:301–325. <https://doi.org/10.1146/annurev.mi.45.100191.001505>.
45. Zhang S, Zhou H, Yu F, Gao F, He J, Liu C. 2016. Functional partition of Cpn60alpha and Cpn60beta subunits in substrate recognition and cooperation with co-chaperonins. *Mol Plant* 9:1210–1213. <https://doi.org/10.1016/j.molp.2016.04.019>.
 46. Weaver J, Rye HS. 2014. The C-terminal tails of the bacterial chaperonin GroEL stimulate protein folding by directly altering the conformation of a substrate protein. *J Biol Chem* 289:23219–23232. <https://doi.org/10.1074/jbc.M114.577205>.
 47. Weaver J, Jiang M, Roth A, Puchalla J, Zhang J, Rye HS. 2017. GroEL actively stimulates folding of the endogenous substrate protein PepQ. *Nat Commun* 8:15934. <https://doi.org/10.1038/ncomms15934>.
 48. Chen D-H, Madan D, Weaver J, Lin Z, Schröder GF, Chiu W, Rye HS. 2013. Visualizing GroEL/ES in the act of encapsulating a folding protein. *Cell* 153:1354–1365. <https://doi.org/10.1016/j.cell.2013.04.052>.
 49. Ogino H, Wachi M, Ishii A, Iwai N, Nishida T, Yamada S, Nagai K, Sugai M. 2004. FtsZ-dependent localization of GroEL protein at possible division sites. *Genes Cells* 9:765–771. <https://doi.org/10.1111/j.1365-2443.2004.00770.x>.
 50. Liu H, and, Naismith JH. 2008. An efficient one-step site-directed deletion, insertion, single and multiple-site plasmid mutagenesis protocol. *BMC Biotechnol* 8:91. <https://doi.org/10.1186/1472-6750-8-91>.
 51. Lanzetta PA, Alvarez LJ, Reinach PS, Candia OA. 1979. An improved assay for nanomole amounts of inorganic phosphate. *Anal Biochem* 100:95–97. [https://doi.org/10.1016/0003-2697\(79\)90115-5](https://doi.org/10.1016/0003-2697(79)90115-5).